Press Release Archive

 
December 18, 2014 - Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia

Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN). The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR) in pain reduction.

 
December 17, 2014 - Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy

Pfizer Inc. (NYSE:PFE) announced today enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. PF-06252616 is an experimental, infused, anti-myostatin monoclonal antibody.

 
December 16, 2014 - Pfizer Invites Public To View And Listen To Webcast Of January 27 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 27, 2015. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2014 Performance Report, to be issued that morning.

 
December 16, 2014 - Meningococcal Meningitis Survivor and TV Personality Amy Purdy and Pfizer Launch Take Action Against Meningitis

Paralympic®* medalist and world class snowboarder Amy Purdy and her mother, Sheri, have teamed up with

 
December 15, 2014 - Pfizer Declares First-Quarter 2015 Dividend

The board of directors of Pfizer Inc. today declared a 28-cent first-quarter 2015 dividend on the company’s common stock, payable March 3, 2015, to shareholders of record at the close of business on February 6, 2015. Pfizer increased the dividend by approximately 8 percent, to 28 cents from 26 cents per share.

 

 
December 15, 2014 - OPKO and Pfizer Enter into Global Agreement for OPKO’s Long-Acting Human Growth Hormone (hGH-CTP)

OPKO Health, Inc. (NYSE:OPK) and Pfizer Inc. (NYSE:PFE) announced today that they have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by 2 years of age.

 
December 10, 2014 - Pfizer and Brenda Strong Encourage Women to Change the Conversation on Sexual Health Post-Menopause

Nearly one out of every two (45.25%) American women will be menopausal or approaching menopause next year. While most women are aware of menopausal symptoms, such as hot flashes and night sweats, fewer know about a condition that affects one-third of women called postmenopausal vaginal atrophy.

 
December 9, 2014 - New Data at ASH 2014 Highlight Progress of Pfizer’s Growing Portfolio in Blood Cancers

Pfizer Inc. (NYSE:PFE) today announced the presentation of encouraging early- and late-stage data from clinical studies across several hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML).

 
December 8, 2014 - Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis (apixaban) by 4-factor prothrombin complex concentrates (PCCs) in healthy subjects.

 
December 8, 2014 - Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform

Pfizer Inc. (NYSE:PFE) announced today two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients.

 
December 2, 2014 - New Survey Finds Majority of Women with Breast Cancer Who Work Want to Do So Even While Undergoing Treatment

A new survey reveals that 77 percent of working women with breast cancer, including those with metastatic disease, feel that working aids in their recovery – a view shared almost unanimously by healthcare professionals, who were also surveyed (92%). The Supporting Workplace Conversations survey is the first to comprehensively examine the perspectives of working women with breast cancer, healthcare professionals and employers on the topic of breast cancer and the workplace.

 
December 1, 2014 - Pfizer Completes Acquisition of Baxter’s Marketed Vaccines

Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of Baxter International Inc.’s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. As previously announced, Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.

 
November 17, 2014 - Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)

Portola Pharmaceuticals (NASDAQ: PTLA), Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies.

 
November 17, 2014 - Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

Pfizer Inc. (NYSE:PFE) announced today that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple types of cancer.

 
November 12, 2014 - Pfizer Highlights Leadership in Rheumatology and Inflammation with Data to be Presented at the ACR/ARHP 2014 Annual Meeting

Pfizer Inc. announced today that it will present data for several of its marketed and investigational medicines for inflammatory and immunological conditions at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2014 Annual Meeting (November 14-19, Boston, Massachusetts).

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.

Current Stock Price

.
.
%Change . 52 Wk. High .
Day High . 52 Wk. Low .
Day Low . Mkt. Cap(Mil) .
Open .
Prev Close . Symbol .
Vol. . Exchange .

Online Pfizer Press Kit

Our press kit provides information that might help you write stories or simply find out more about Pfizer.